Summary
Vertex Pharmaceuticals Inc. demonstrated strong financial performance in 2017, marked by a significant increase in total revenues to $2.5 billion and a return to profitability, with net income attributable to Vertex reaching $263.5 million. This turnaround was largely driven by robust growth in net product revenues for its cystic fibrosis (CF) treatments, ORKAMBI and KALYDECO, which collectively generated $2.17 billion. The company also received a substantial $230 million upfront payment from its collaboration with Merck KGaA for oncology programs. The company is strategically focused on advancing its pipeline, particularly its next-generation CFTR corrector triple combination therapies (VX-659 and VX-445), which are entering Phase 3 clinical trials. These therapies hold the potential to treat a significantly larger portion of CF patients. Vertex also secured FDA approval for SYMDEKO (tezacaftor/ivacaftor) in February 2018, adding another treatment option for CF patients. Beyond CF, Vertex is pursuing drug candidates for pain, hemoglobinopathies (in collaboration with CRISPR Therapeutics), and spinal cord injuries, showcasing a diversified R&D strategy. Key risks identified include the company's heavy reliance on CF products, potential competition, challenges in securing international reimbursement, and the inherent uncertainties in drug development. Despite these risks, Vertex's financial recovery and strong pipeline progression position it for continued growth, contingent on the successful development and commercialization of its next-generation therapies.
Financial Highlights
53 data points| Revenue | $2.49B |
| Cost of Revenue | $272.68M |
| Gross Profit | $2.22B |
| R&D Expenses | $1.32B |
| SG&A Expenses | $496.08M |
| Operating Expenses | $2.37B |
| Operating Income | $123.24M |
| Interest Expense | $69.30M |
| Net Income | $263.48M |
| EPS (Basic) | $1.06 |
| EPS (Diluted) | $1.04 |
| Shares Outstanding (Basic) | 248.86M |
| Shares Outstanding (Diluted) | 253.22M |
Key Highlights
- 1Total revenues increased by 46% to $2.5 billion in 2017, driven by a 29% increase in product revenues to $2.17 billion, primarily from ORKAMBI and KALYDECO.
- 2Vertex returned to profitability in 2017, reporting a net income attributable to Vertex of $263.5 million, a significant improvement from a net loss of $112.1 million in 2016.
- 3SYMDEKO (tezacaftor in combination with ivacaftor) received FDA approval in February 2018, providing an additional treatment option for CF patients.
- 4The company advanced two next-generation CFTR corrector compounds, VX-659 and VX-445, into Phase 3 clinical development for triple combination regimens, aiming to treat a wider CF patient population.
- 5Significant R&D investment continues, with $1.3 billion spent in 2017, including $160 million for the acquisition of VX-561.
- 6Vertex received a $230 million upfront payment from Merck KGaA in 2017 for an oncology collaboration, bolstering its collaborative revenues.
- 7The company reported $2.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2017, indicating strong liquidity.